Crown Bioscience Expands Cardiovascular & Metabolic Disease Research Capability
The Company Offers New Non-GLP Services & Translational Rodent Models at its expanded site in Louisiana
SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced the expansion of its New Iberia, Louisiana research facilities to support novel capabilities including non-GLP clinical chemistry, biomarker services and proprietary early stage preclinical models.
With this enhancement CrownBio will focus on cardio-metabolic endpoints to cost effectively deliver robust, high-quality sample analysis data as a standalone service, or as a supplement to in vivo studies, which will provide valuable information about drug efficacy, candidate selection and enzymatic activity.
The Company has also added an electrochemiluminescent technology platform to its on-site research capabilities, allowing clients to investigate the disease pathophysiology and the agents’ mechanism of action.
This expansion follows CrownBio’s 2017 investment at the New Iberia Research Center (NIRC) to house its exclusive FATZO and ZDSD polygenic models for obesity, metabolic syndrome and diabetes translational research, in fully renovated, state-of-the art facilities that benefit from AAALAC, OLAW and USDA accreditations.
“We are incredibly pleased with the outcome of our renovation and expansion,” stated Keefe Chng, General Manager and CSO of CrownBio Louisiana. “The addition of the FATZO and ZDSD preclinical models to our platform at CrownBio Louisiana is a significant step forward in our capabilities at this site.”
“Our clients are thrilled to have access to an analytical lab onsite,” said Jim Wang, Senior Vice President of CrownBio’s Cardiovascular and Metabolic Disease division. “These platforms allow us to rapidly and cost-effectively analyze samples thereby enabling our clients to get their compounds to the clinic sooner.”
To learn more about CrownBio’s new clinical chemistry and biomarker services, visit https://www.crownbio.com/reliable-clinical-chemistry-biomarker-services
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc. firstname.lastname@example.org
Upcoming Life Sciences Events
- February 2019
- Zurich: 12th Annual European Life Sciences CEO Forum
- March 2019
- Tokyo: BIO Asia International Conference
- Singapore: Phar-East 2019